Discrete states for use as biomarkers
OwnerManfred Beleut, Peter Schraml +5inventors
InventorsManfred Beleut, Peter Schraml, Holger Moch, Michael Baudis, Philip Zimmermann, Wilhelm Gruissem, Karsten Henco
Life of this patent
Estimating the term…
Abstract
The present invention describes the use of discrete states and signatures for classifying samples.
Claims15
A method of diagnosing, prognosing, stratifying and/or screening renal cell carcinoma (RCC) in at least one human or animal patient suspected of being afflicted with RCC comprising the steps of:
- (a) providing a sample of a human or animal individual suspected to suffer from RCC;
- (b) testing the sample for a signature indicative of a discrete RCC-specific state by determining expression of at least 6 genes of Table 10;
- and
- (c) allocating a discrete RCC-specific state to the sample based on the signature determined in step (b).
A method of determining the responsiveness of at least one human or animal individual suspected of being afflicted with RCC towards a pharmaceutically active agent comprising the steps of:
- (a) providing a sample of a human or animal individual suspected to suffer from RCC before the pharmaceutically active agent is administered;
- (b) testing the sample for a signature indicative of a discrete RCC-specific state by determining expression of at least 6 genes of Table 10;
- (c) allocating a discrete RCC-specific state to the sample based on the signature determined in step (b);
- (d) determining the effects of the pharmaceutically active agent on the disease symptoms in the individual;
- and
- (e) identifying a correlation between the effects on disease symptoms and/or discrete RCC-specific states and the initial discrete RCC-specific state of the sample.
A method of determining the effects of a potential pharmaceutically active compound for treatment of RCC, comprising the steps of:
- (a) providing a sample of a human or animal individual suspected to suffer from RCC before a pharmaceutically active agent is applied;
- (b) testing the sample from step (a) for a signature indicative of a discrete RCC-specific state by determining expression of at least 6 genes of Table 10;
- (c) allocating a discrete RCC-specific state to the sample from step (a) based on the signature determined in step (b);
- (d) providing a sample of the same human or animal individual suspected to suffer from RCC after a pharmaceutically active agent is applied;
- (e) testing the sample from step (d) for a signature indicative of a discrete RCC-specific state by determining expression of at least 6 genes of Table 10;
- (f) allocating a discrete RCC-specific state to the sample from step (d) based on the signature determined in step (e);
- and
- (g) comparing the discrete RCC-specific states identified in steps (c) and (f).
A signature which is defined by the expression pattern of at least 6 genes of Table 10 for use in diagnosing, prognosing, stratifying and/or screening renal cell cancer in human or animal individuals.
A signature which is defined by the expression pattern of at least 6 genes of Table 10 for use as a read out of a target for development, identification and/or screening of at least one pharmaceutically active compound for treatment of renal cell cancer.
Dependencies are inferred from the claim text.